Technologies
PDF


WARF: P07035US

Novel Splice Variants of PIPKIgamma Provide Biomarkers for Breast Cancer Diagnosis and Prognosis


INVENTORS -

Richard Anderson, Nicholas Schill

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing novel biomarkers that could be used to monitor the progression of epithelial cancers, including breast cancer.
OVERVIEWAccording to the Centers for Disease Control and Prevention, more than 185,000 women in the U.S. were diagnosed with breast cancer and more than 40,000 died as a result of the disease in 2005.  It is difficult to predict how the disease will progress in a given patient.  Identifying individuals with poor prognosis may enable more informed treatment decisions, but few markers of breast cancer progression are available.

Type I phosphatidylinositol phosphate kinases (PIPKIs) may provide additional cancer biomarkers.  In mammals, phosphatidylinositol-based signaling pathways play crucial roles in the regulation of cell processes at the plasma membrane and in the nucleus. At least three isoforms of PIPKI exist, and these isoforms are expressed at different times and locations.  One of the isoforms, PIPKIgamma, binds E-cadherin, a known breast cancer biomarker, and controls its function.
THE INVENTIONUW-Madison researchers have identified novel variants of PIPKIgamma that could be used to monitor breast cancer progression and determine prognosis.  The variants correlate with key markers of breast cancer progression, including the loss of E-cadherin and increased HER1 or HER2 expression.
APPLICATIONS
  • Monitoring breast cancer progression
  • Diagnosing poor prognosis for breast cancer
  • Monitoring other epithelial cancers, including ovarian, uterine, prostate and skin cancer
KEY BENEFITS
  • Provides new validated biomarkers for breast cancer progression and prognosis
  • Complements existing biomarkers
  • Useful for other cancers in additional to breast cancer
  • Allows physicians and patients to make more informed treatment decisions
  • Could be used to identify agents that bind or modulate these variants
STAGE OF DEVELOPMENTSuccessfully tested in an archived collection of 438 samples.
ADDITIONAL INFORMATION
For More Information About the Inventors
Related Intellectual Property
Contact Information
For current licensing status, please contact Joshua Carson at jcarson@warf.org or 608-960-9844.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.